Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dose Medical Corporation currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner in 1 distinct art unit. This indicates a highly focused prosecution effort for the company's current filings. For a practitioner, this means that the entire prosecution strategy is focused on the standards of a single art unit and the specific expectations of one examiner.
AZPURU, CARLOS A is the busiest examiner for the portfolio, with 1 pending office action. This examiner is the sole individual currently processing the company's pending action. The use of 1 distinct art unit for this action suggests the pharmaceutical technology is classified within a single specialized group. This concentration allows for a very specific and consistent dialogue during the prosecution of the current application, as there are no other pending matters or examiners to coordinate with at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18424641 | BIOERODIBLE POLYESTER POLYMER AXITINIB OCULAR IMPLANTS AND RELATED METHODS OF USE | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18424641 | BIOERODIBLE POLYESTER POLYMER AXITINIB OCULAR IMPLANTS AND RELATED METHODS OF USE | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18424641 | BIOERODIBLE POLYESTER POLYMER AXITINIB OCULAR IMPLANTS AND RELATED METHODS OF USE | AZPURU, CARLOS A | 1617 | §112 | Final Rejection | — | Pending | Jan 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDose Medical Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carlos A Azpuru has the most, with 1 of Dose Medical Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
